A Phase 1/2a, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, and Efficacy of RZ-001 in Combination with Valganciclovir in Subjects with Glioblastoma
Latest Information Update: 08 Nov 2024
Price :
$35 *
At a glance
- Drugs RZ-001 (Primary)
- Indications Astrocytoma; Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Rznomics
- 06 Aug 2024 Status changed from not yet recruiting to recruiting.
- 26 Jul 2024 Planned initiation date changed from 1 Oct 2023 to 1 Aug 2024.
- 25 May 2023 New trial record